Table 2 Comparison of changes in vision and central retinal thickness: baseline vs 1 year and subgroup analyses

From: Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result

 

Total RVO, n=66

CRVO, n=29

HRVO, n=9

BRVO, n=28

Comparison of visual acuity (VA) in LogMAR (Snellen equivalent)

 Baseline: median VA (IQR)

0.71 (6/30) (0.43–1.16)

1.00 (6/60) (0.52–1.41)

0.72 (6/30) (0.41–1.05)

0.60 (6/24) (0.3–0.78)

 aPostloading: median VA (IQR)

0.48 (6/18) (0.18–0.84)

   
 

P<0.001

   

 One year: median VA (IQR)

0.48 (6/18) (0.18–0.78)

0.78 (6/36) (0.48–1.14)

0.44 (6/15) (0.15–0.54)

0.54 (6/20) (0.30–0.78)

 

P<0.001

P=0.055

P=0.033

P<0.001

One year of visual changes

 Worse

10 (15%)

8 (28%)

1 (11%)

1 (4%)

 Stable

5 (8%)

2 (7%)

1 (11%)

3 (11%)

 Improved

51 (77%)

19 (66%)

7 (78%)

17 (61%)

 Improved by 3 lines

34 (52%)

13 (45%)

4 (44%)

16 (57%)

 Achieved 6/12 or better

30 (45.5%)

   

Comparison of central retinal thickness (CRT) changes in μm

 Baseline: median CRT (IQR)

531 (435–622)

571 (466–663)

513 (430–559)

499 (403–553)

 aPost loading: median CRT (IQR)

239 (215–290)

   
 

P<0.001

   

 One year: median CRT (IQR)

245 (221–351)

236 (208–332)

285 (243–386)

252 (224–347)

 

P<0.001

P<0.001

P=0.009

P<0.001

  1. Abbreviations: BRVO, branch retinal vein occlusion; IQR, interquartile-range (statistical analysis using Wilcoxon signed-rank test); CRVO, central retinal vein occlusion; HRVO, hemi-retinal vein occlusion; RVO, retinal vein occlusion.
  2. aSubgroup analyses on VA and CRT were not performed in the postloading phase.
Back to article page